CHO based biosimilar cell lines

Bioceros has developed a portfolio of high producing cell lines expressing biosimilar proteins, such as fusion proteins, enzymes and monoclonal antibodies which are available for out-licensing.

These biosimilar cell lines are generated on our proprietary CHO-based platform, CHOBC® using (animal component free) of the shelf culture medium. The cell lines are GMP-ready, stable, high producing, fully documented and functionally characterized. All available QA approved documentation is accessible for our (potential) partners via a Virtual Data Room.

Biosimilar programs that are completed and ready for tech transfer to a CMO of choice by our partner, as well as programs in different development stages, can be found in the table below.

For more information please contact J. Jansma at j.jansma@bioceros.com or call +31 88 9956 343

Designation

Biosimilar to

Antibody

Status

BC002 Herceptin® Trastuzumab Lead cell line available for purchase
BC004 Humira® Adalimumab Lead cell line available for purchase
BC005 Erbitux® Cetuximab Lead cell line available for purchase
BC006 Avastin® Bevacizumab Lead cell line available for purchase
BC007 Rituxan/MabThera® Rituximab Lead cell line available for purchase
BC008 Enbrel® Etanercept Lead cell line available for purchase
BC009 Synagis® Palivizumab Lead cell line available for purchase
BC011 Xolair® Omalizumab Lead cell line available for purchase
BC017 Yervoy® Ipilimumab Process available for purchase
BC019 Perjeta® Pertuzumab Process available for purchase
BC022 Opdivo® Nivolumab Upstream process under development
BC023 Keytruda® Pembrolizumab Upstream process under development